Biocon Biologic's Malaysian arm recognized as largest integrated insulin manufacturer by MBR

5 Aug 2022 , 02:20 PM

Biocon Limited announced that Biocon Biologic’s subsidiary Biocon Sdn. Bhd., Malaysia has entered the prestigious Malaysia Book of Records (MBR).

MBR recognised the company’s 562,000 sq. ft. facility as the first and largest integrated insulin manufacturer in Malaysia. MBR officially recognises record-breaking and record-creating achievements in Malaysian fields such as human endeavour, building & structures, transportation, arts & entertainment, business, sports & games, science & technology, nature, and so on.

Biocon Biologics has established an insulin Center of Excellence (CoE) in Malaysia, with end-to-end capabilities to manufacture a diverse portfolio of regular, basal, and rapid insulins.

The state-of-the-art insulins facility in Johor is Malaysia’s first and only biopharmaceutical sterile injectables facility to be approved by the USFDA and the European Medicines Agency.

More recently, Biocon’s biosimilar insulin Glargine, manufactured in Malaysia, was approved by the USFDA as the “first interchangeable biosimilar.”

Biocon Biologics has invested over USD 350 million in Malaysia’s largest integrated insulin manufacturing and R&D facility, Biocon Sdn Bhd.

Commercial operations at the facility began in 2016 when Biocon Biologics’ recombinant human insulin was approved for sale in Malaysia as the first locally manufactured biosimilar product.

At around 2.24 PM, Biocon was trading at Rs313.10 down by Rs0.75 or 0.24% from its previous closing of Rs313.85 on the BSE. The scrip touched intraday high and low of Rs316.15 and Rs312.55 respectively.